Equity Bank Uganda and Equity Bank Kenya are moving forward with the planned auction of properties belonging to businessman Dr Mathias Magoola's companies, Dei BioPharma Ltd and Dei Industries International Ltd, to recover over Shs 148 billion in outstanding loans. The banks have confirmed that the auction, scheduled to take place through public auction or private treaty, is lawful and not in contempt of any court proceedings.

The proposed auction, announced by JALD (U) Ltd on November 5, 2026, lists several commercial, industrial, and residential properties in Kampala and Wakiso districts, including a pharmaceutical manufacturing facility at Matugga, a wheat milling plant in Luzira, and properties in Kyamuli-Kungu, Katwe, Muyenga, Kitende, and Seguku. The Matugga establishment, associated with Dei's pharmaceutical manufacturing project, occupies approximately 20.673 acres.

The auction has exposed a longstanding dispute between the banks and Dei companies over outstanding loan balances and the process used to establish the amounts owed. Dei's lawyers, Muwema and Company Advocates, have argued that the auction is premature because the outstanding debt remains contested and court proceedings relating to the loan audit have not been concluded.

The dispute escalated after the Court of Appeal reportedly stayed proceedings in the underlying High Court case on September 9, 2026, pending determination of an appeal relating to the contested audit process. However, the banks maintain that the court order does not prevent them from exercising their rights under the mortgages securing the loans.

Through their lawyers, Katende, Ssempebwa and Company Advocates, the banks have urged members of the public to disregard a warning published by Muwema and Company Advocates on November 9, 2026, cautioning prospective buyers against purchasing the properties. The banks have confirmed that there is no court order staying or stopping the proposed sale.

The planned disposal has attracted public interest due to the government's reported investment of Shs 723.4 billion in Dei BioPharma, which is developing a pharmaceutical manufacturing facility at Matugga. The Parliamentary Committee on Presidential Affairs has previously raised concerns about accountability, operational performance, and documentation relating to the government's investment in the company.

The competing legal notices leave prospective buyers with conflicting positions from the two sides over the proposed transaction. While the banks have invited the public to participate in the auction, Dei's lawyers have cautioned against purchasing the properties, arguing that the sale is being pursued before the loan dispute is resolved.

Key points

  • The auction of Dei properties is proceeding despite a legal warning issued to prospective buyers.
  • The dispute between Equity Bank and Dei companies centers on outstanding loan balances and the audit process used to establish the amounts owed.
  • The government's investment in Dei BioPharma has raised concerns about accountability and operational performance.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.